FIELD: pharmaceutical industry.
SUBSTANCE: dosage form for high density lipoprotein (HDL-c) cholesterol in a subject contains fat of marine animals containing fatty acids, including omega-3 polyunsaturated fatty acids (PUFA), where 4Z, 7Z, 10Z, 13Z, 16Z, 19Z-docosahexaenoic acid (DHA) and 5Z, 8Z, 11Z, 14Z, 17Z-eicosapentaenoic acid (EPA) contain at least part of PUFA, where the amount of DHA is from 450 to 700 mg, and the amount of EPA is from 150 to 300 mg, where at least 50 % of fatty acids are interesterified triglycerides (rTG), and where the dosage form is an oral dosage form. Also disclosed is a method of increasing high-density lipoprotein cholesterol 25 (HDL-c) in a subject.
EFFECT: group of inventions provides protection from cardiovascular diseases.
26 cl, 30 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM | 2013 |
|
RU2664429C2 |
| COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS | 2013 |
|
RU2645075C2 |
| LIPIDS CONTAINING FATTY ACIDS OMEGA-3 AND OMEGA-6 | 2004 |
|
RU2362566C2 |
| COMBINATION OF OMEGA-3 FATTY ACID AND SGLT-2 INHIBITOR FOR TREATING LIVER DISEASES | 2015 |
|
RU2695652C2 |
| TREATMENT METHODS WHICH REQUIRE PHYTOCOMPONENTS | 2005 |
|
RU2394576C2 |
| FOOD PRODUCT FOR DIABETICS | 2005 |
|
RU2380983C2 |
| CONCENTRATED THERAPEUTIC PHOSPHOLIPIDE COMPOSITIONS | 2010 |
|
RU2642653C2 |
| CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS | 2010 |
|
RU2755902C2 |
| LIPID MIXTURE FOR INFANT ALIMENTATION | 2008 |
|
RU2488283C2 |
| DIET COMPOSITION IN CASE OF OSTEOARTHRITIS IN DOGS | 2005 |
|
RU2351153C2 |
